Idogen AB logo

IDOGEN - Idogen AB Share Price

SEK5.06 0.0  0.0%

Last Trade - 28/09/20

Micro Cap
Market Cap £4.09m
Enterprise Value £985k
Revenue £n/a
Position in Universe 1667th / 1785
Unlock IDOGEN Revenue
Relative Strength (%)
1m -11.8%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -58.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Idogen AB revenues was not reported. Net loss decreased 21% to SEK14.2M. Lower net loss reflects Depreciation & Amortization decrease of 87% to SEK662K (expense), Other Operating Income increase from SEK2M to SEK4.2M (income), Personal Expenses decrease of 3% to SEK6M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -SEK0.37 to -SEK1.00.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


IDOGEN Revenue Unlock IDOGEN Revenue

Net Income

IDOGEN Net Income Unlock IDOGEN Revenue

Normalised EPS

IDOGEN Normalised EPS Unlock IDOGEN Revenue

PE Ratio Range

IDOGEN PE Ratio Range Unlock IDOGEN Revenue

Dividend Yield Range

IDOGEN Dividend Yield Range Unlock IDOGEN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IDOGEN EPS Forecasts Unlock IDOGEN Revenue
Profile Summary

Idogen AB is a Sweden-based company engaged in the healthcare industry. The Company is a research-driven entity developing a so called Tolerogenic Vaccine, a treatment concept for anti-drug antibodies, autoimmune diseases and transplant rejection. Its treatment is based on the patient's own dendritic cells (a type of white blood cell) and is taken out and reprogrammed in vitro and then given back to the patient. The Company is in pre-clinical phase and owns a platform technology, from which Idogen AB develops treatment for anti-drug antibodies, as well as autoimmune diseases that cannot be cured. In addition, the Company focuses on the transplantation market by reducing the need for immunosuppressive therapy after transplantation.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since June 12, 2015
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 9,371,654
Free Float (0.0%)
Eligible for
IDOGEN Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for IDOGEN
Upcoming Events for IDOGEN
Frequently Asked Questions for Idogen AB
What is the Idogen AB share price?

As of 28/09/20, shares in Idogen AB are trading at SEK5.06, giving the company a market capitalisation of £4.09m. This share price information is delayed by 15 minutes.

How has the Idogen AB share price performed this year?

Shares in Idogen AB are currently trading at SEK5.06 and the price has moved by -56.53% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Idogen AB price has moved by -51.32% over the past year.

What are the analyst and broker recommendations for Idogen AB?

Of the analysts with advisory recommendations for Idogen AB, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for Idogen AB is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will Idogen AB next release its financial results?

Idogen AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Idogen AB dividend yield?

Idogen AB does not currently pay a dividend.

Does Idogen AB pay a dividend?

Idogen AB does not currently pay a dividend.

When does Idogen AB next pay dividends?

Idogen AB does not currently pay a dividend.

How do I buy Idogen AB shares?

To buy shares in Idogen AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Idogen AB?

Shares in Idogen AB are currently trading at SEK5.06, giving the company a market capitalisation of £4.09m.

Where are Idogen AB shares listed? Where are Idogen AB shares listed?

Here are the trading details for Idogen AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: IDOGEN
What kind of share is Idogen AB?

Based on an overall assessment of its quality, value and momentum, Idogen AB is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Idogen AB share price forecast 2020?

Shares in Idogen AB are currently priced at SEK5.06. At that level they are trading at 27.08% premium to the analyst consensus target price of 0.00.

Analysts covering Idogen AB currently have a consensus Earnings Per Share (EPS) forecast of -32.92 for the next financial year.

How can I tell whether the Idogen AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Idogen AB. Over the past six months, the relative strength of its shares against the market has been -13.18%. At the current price of SEK5.06, shares in Idogen AB are trading at -21.16% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Idogen AB PE Ratio?

We were not able to find PE ratio data for Idogen AB.

Who are the key directors of Idogen AB?

We were unable to find the directors for Idogen AB.

Who are the major shareholders of Idogen AB?

Here are the top five shareholders of Idogen AB based on the size of their shareholding:

Similar to IDOGEN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.